WP
QNCX icon

Woodline Partners’s Quince Therapeutics QNCX Stock Holding History

Woodline Partners’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$527K Buy
26,000
+16,292
+168% +$3.27M ﹤0.01% 955
2025
Q4 		$6.5M Buy
+9,708
New +$4.88M 0.03% 565

Other funds holding QNCX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Woodline Partners's QNCX Position: Q1 2026 in Review

Woodline Partners increased its Quince Therapeutics (QNCX) stake by 168% in Q1 2026, buying an estimated $3.27M and bringing the position to 26,000 shares worth $527K. The position accounts for ﹤0.01% of the portfolio, ranked #955.

Woodline Partners first reported a position in QNCX in Q4 2025 and has held it in 2 quarters since. The position peaked at $6.5M in Q4 2025. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Woodline Partners held 26,000 shares of Quince Therapeutics worth $527K as of Q1 2026.
  • Woodline Partners bought 16,292 Quince Therapeutics shares in Q1 2026, an estimated $3.27M.
  • Quince Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q1 2026, its #955 holding.
  • Woodline Partners first reported a position in Quince Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Woodline Partners's Quince Therapeutics position peaked at $6.5M in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.